Ubs Asset Management Americas Inc Dynavax Technologies Corp Transaction History

Ubs Asset Management Americas Inc

  • $446 Billion
  • Q3 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 287,185 shares of DVAX stock, worth $3.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
287,185
Previous 492,725 41.71%
Holding current value
$3.18 Million
Previous $4.89 Million 41.66%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
$9.36 - $11.36 $1.92 Million - $2.33 Million
-205,540 Reduced 41.71%
287,185 $2.85 Million
Q2 2025

Aug 14, 2025
BUY
$9.4 - $12.87 $400,778 - $548,725
42,636 Added 9.47%
492,725 $4.89 Million
Q1 2025

May 19, 2025
BUY
$12.39 - $14.4 $368,775 - $428,601
29,764 Added 7.08%
450,089 $5.84 Million
Q4 2024

Feb 14, 2025
BUY
$10.28 - $13.66 $1.17 Million - $1.56 Million
113,872 Added 37.16%
420,325 $5.37 Million
Q3 2024

Nov 14, 2024
SELL
$10.05 - $11.61 $2,412 - $2,786
-240 Reduced 0.08%
306,453 $3.41 Million
Q2 2024

Aug 13, 2024
BUY
$10.73 - $12.58 $1.52 Million - $1.78 Million
141,261 Added 85.39%
306,693 $3.44 Million
Q4 2023

Feb 14, 2024
BUY
$13.09 - $14.98 $54,323 - $62,167
4,150 Added 2.57%
165,432 $2.31 Million
Q3 2023

Nov 13, 2023
BUY
$12.64 - $14.99 $375,584 - $445,412
29,714 Added 22.58%
161,282 $2.38 Million
Q1 2023

May 15, 2023
BUY
$9.44 - $11.88 $143,639 - $180,766
15,216 Added 13.08%
131,568 $1.29 Million
Q3 2022

Nov 14, 2022
SELL
$9.93 - $17.44 $11,955 - $20,997
-1,204 Reduced 1.02%
116,352 $1.21 Million
Q2 2022

Aug 12, 2022
SELL
$7.45 - $12.83 $7,472 - $12,868
-1,003 Reduced 0.85%
117,556 $1.48 Million
Q4 2021

Feb 14, 2022
BUY
$13.17 - $20.94 $17,094 - $27,180
1,298 Added 1.11%
118,559 $1.67 Million
Q3 2021

Nov 15, 2021
SELL
$9.16 - $19.83 $179,710 - $389,044
-19,619 Reduced 14.33%
117,261 $2.25 Million
Q2 2021

Aug 16, 2021
BUY
$7.25 - $10.99 $131,623 - $199,523
18,155 Added 15.29%
136,880 $1.35 Million
Q1 2021

May 14, 2021
SELL
$4.57 - $11.18 $863 - $2,113
-189 Reduced 0.16%
118,725 $1.17 Million
Q4 2020

Mar 01, 2021
BUY
$3.73 - $5.6 $150,908 - $226,564
40,458 Added 51.57%
118,914 $529,000
Q3 2020

Nov 13, 2020
SELL
$4.32 - $11.7 $6.79 Million - $18.4 Million
-1,571,844 Reduced 95.25%
78,456 $338,000
Q2 2020

Aug 14, 2020
BUY
$2.94 - $9.1 $12,330 - $38,165
4,194 Added 0.25%
1,650,300 $14.6 Million
Q1 2020

May 15, 2020
SELL
$2.27 - $6.2 $215,650 - $589,000
-95,000 Reduced 5.46%
1,646,106 $5.81 Million
Q4 2019

Feb 14, 2020
SELL
$3.46 - $6.93 $21,362 - $42,785
-6,174 Reduced 0.35%
1,741,106 $9.96 Million
Q3 2019

Nov 14, 2019
BUY
$2.69 - $4.85 $14,453 - $26,059
5,373 Added 0.31%
1,747,280 $6.26 Million
Q2 2019

Aug 15, 2019
BUY
$3.65 - $7.89 $3.23 Million - $6.98 Million
884,854 Added 103.24%
1,741,907 $0
Q1 2019

May 14, 2019
BUY
$7.08 - $12.09 $69,426 - $118,554
9,806 Added 1.16%
857,053 $0
Q4 2018

Feb 13, 2019
BUY
$8.14 - $13.28 $2.4 Million - $3.92 Million
294,912 Added 53.39%
847,247 $7.75 Million
Q3 2018

Nov 14, 2018
SELL
$11.85 - $16.0 $416,349 - $562,160
-35,135 Reduced 5.98%
552,335 $0
Q2 2018

Aug 14, 2018
SELL
$15.15 - $20.75 $49,616 - $67,956
-3,275 Reduced 0.55%
587,470 $0
Q1 2018

May 14, 2018
BUY
$14.65 - $19.9 $8.29 Million - $11.3 Million
565,885 Added 2276.29%
590,745 $0
Q4 2017

Feb 09, 2018
SELL
$17.3 - $24.08 $8.63 Million - $12 Million
-498,635 Reduced 95.25%
24,860 $0
Q3 2017

Nov 13, 2017
BUY
$15.2 - $21.5 $7.96 Million - $11.3 Million
523,495
523,495 $0

Others Institutions Holding DVAX

# of Institutions
304
Shares Held
120M
Call Options Held
293K
Put Options Held
311K
View Full List

About DYNAVAX TECHNOLOGIES CORP

DVAX Quotes by TradingView
  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.4B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email